Membranous Nephropathy: A Journey From Bench to Bedside

Jean M. Francis, MD, Laurence H. Beck Jr, MD, PhD, and David J. Salant, MD

Lessons from an animal model that faithfully resembles human membranous nephropathy (MN) have informed our understanding of the pathogenesis of this organ-specific autoimmune disease and common cause of nephrotic syndrome. After it was established that the subepithelial immune deposits that characterize experimental MN form in situ when circulating antibodies bind to an intrinsic podocyte antigen, it was merely a matter of time before the human antigen was identified. The M-type phospholipase A2 receptor 1 (PLA2R) represents the major target antigen in primary MN, and thrombospondin type 1 domain-containing 7A (THSD7A) was more recently identified as a minor antigen. Serologic tests for anti-PLA2R and kidney biopsy specimen staining for PLA2R show >90% specificity and 70% to 80% sensitivity for the diagnosis of primary MN in most populations. The assays distinguish most cases of primary MN from MN associated with other systemic diseases, and sequential anti-PLA2R titers are useful to monitor treatment response. A positive pretransplantation test result for anti-PLA2R is also helpful for predicting the risk for posttransplantation recurrence. Identification of target epitopes within PLA2R and the genetic association of primary MN with class II major histocompatibility and PLA2R1 variants are 2 additional examples of our evolving understanding of this disease.

INDEX WORDS: Membranous nephropathy (MN); nephrotic syndrome; M-type phospholipase A2 receptor 1 (PLA2R); PLA2R1; thrombospondin type 1 domain-containing 7A (THSD7A); organ-specific autoimmunity; class II major histocompatibility; genetic polymorphisms; post-transplant recurrent disease; epitope.

David J. Salant, MD, was the Donald W. Seldin Distinguished Award recipient at the 2015 National Kidney Foundation Spring Clinical Meetings. This award was established to recognize excellence in clinical nephrology in the tradition of one of the foremost teachers and researchers in the field, Dr Donald W. Seldin.

In the late 1970s, 2 groups of investigators, one based in the Netherlands and the other in Boston, MA, were studying Heymann nephritis, a rat model of experimental membranous nephropathy (MN), and made an observation that changed our understanding about the pathogenesis of MN.1-3 Until that time, it was believed that all forms of immune-complex glomerulonephritis (ie, those characterized by granular immune deposits on immunofluorescence [IF] and electron densities on electron microscopy) were due to circulating immune complexes passively trapped in glomeruli. However, the new work conclusively showed that the deposits in experimental MN formed in situ when circulating immunoglobulin G (IgG) antibodies bound to a yet to be characterized intrinsic glomerular antigen.3 Although the location of the intrinsic antigen on the glomerular capillary wall was not defined, we speculated that it might be a component of the visceral epithelial cell (podocyte) surface.1 Some years later, a confluence of studies from several groups identified megalin, a large transmembrane protein member of the low-density lipoprotein receptor family, as the intrinsic antigen and showed that it is expressed on the soles of podocyte foot processes, where it can be engaged by circulating IgG antibodies.4-8 This finding led to a search for anti-megalin antibodies in patients with MN, which proved futile: human podocytes do not express megalin, although it is abundant in the human proximal tubular brush border.8 This, and the failure by several investigators to identify another candidate podocyte antigen, created some doubt about whether the in situ paradigm established in Heymann nephritis also applied to human MN. This doubt was finally dispelled in 2002: interest in the identity of one or more podocyte antigens in human MN was rekindled when Debiec et al9 described a remarkable case of neonatal MN in which transplacental passage of anti-neutral endopeptidase (NEP) antibodies from a presensitized NEP-deficient mother bound to NEP on the baby’s podocytes.

MN is a common cause of nephrotic syndrome in adults, with a peak occurrence in decades 5 to 6, although the age range of onset is broad.10 Most cases (~80%) are primary (formerly called idiopathic MN), but MN may be secondary to systemic lupus.
erythematous (class V lupus nephritis), infection with hepatitis B virus or other agents, solid cancers, and various drugs or toxins. MN may also occur as the result of an alloimmune response, for example, de novo MN after kidney transplantation and during chronic graft-versus-host disease after allogeneic stem cell transplantation, and also as neonatal MN, as noted previously. Primary MN is an organ-specific autoimmune disease. The characteristic pathologic features are a noninflammatory glomerular lesion with glomerular basement membrane thickening (often seen as spike-like extrusions or craters in the glomerular basement membrane) on Jones silver stain, granular capillary wall deposits of IgG and complement on IF, and subepithelial immune deposits on electron microscopy with extensive podocyte foot-process effacement. Primary MN may be distinguished from secondary MN by its predominant IgG4 and absent C1q. The clinical course is variable, with spontaneous remission reported in up to one-third of cases and progression to end-stage renal disease (ESRD) in a similar number. Recurrence of primary MN after kidney transplantation is common and may lead to transplant loss, as we discuss later.

In 2009, we reported on the identification of the M-type phospholipase A2 receptor (PLA2R) as a major target antigen in human primary MN. This finding followed several years of experimentation with extracts of normal human glomeruli and MN patient sera using Western blotting and mass spectrometry and the serendipitous discovery that human MN autoantibodies only recognize the antigen PLA2R under nonreducing conditions (ie, the epitope[s] identified by anti-PLA2R are conformation dependent). Our initial studies also showed that PLA2R is expressed on podocytes and that anti-PLA2R autoantibodies are present in a high proportion of, but not all, cases of primary MN; are predominantly of the IgG4 subclass (as is true of the immune deposits from which they can be eluted); are uniquely present in primary and not secondary MN; and are correlated with disease activity. As in the Heymann nephritis model, we also found that the distribution of PLA2R shifted to become readily detectable in immune deposits in primary but not secondary MN (Fig 1), a finding that has been adopted by nephropathologists to define PLA2R-associated MN. Interestingly, our initial studies identified another putative antigen in a small number of anti-PLA2R-negative cases that ultimately proved to be a second podocyte antigen: thrombospondin type 1 domain-containing 7A (THSD7A). Like PLA2R, THSD7A is expressed on podocytes and redistributes to form the subepithelial immune deposits. It may account for up to 5% of cases of primary MN in Western countries, but has been reported in 9.1% of Japanese patients with primary MN, with an equal prevalence among women and men (Box 1).

Our 2009 report stimulated renewed interest in primary MN and led to the development of diagnostic tests, investigation of the genetic basis of MN, and exploration of the target epitope(s). As commercial immunoassays for anti-PLA2R become more widely used and more nephropathologists perform immunostaining of kidney biopsy specimens for PLA2R, the value for these tests will become increasingly clear for the diagnosis and treatment of primary MN, the exclusion of secondary causes (especially cancer), and the prediction of posttransplantation recurrence. In this review, we focus on developments since the initial discovery of PLA2R as a major target antigen in primary MN. The reader is referred elsewhere for updated discussions of the treatment of MN.

Are the Available Serum Assays for Anti-PLA2R Sensitive and Specific in Predicting Primary MN?

Anti-PLA2R antibody has proved to be a valuable biomarker for the diagnosis of primary MN. It is also useful for monitoring disease activity and predicting

Figure 1. Immunofluorescence micrographs of kidney biopsy specimens from patients with (A, B) primary membranous nephropathy (MN) and (C) membranous lupus nephritis stained for (A) immunoglobulin G (IgG) and (B, C) phospholipase A2 receptor (PLA2R). Note the bright staining for PLA2R in immune deposits in primary MN but not in lupus MN. Abbreviation: IMN, idiopathic membranous nephropathy.
disease recovery and relapse. Depending on the state of disease activity, and as discussed in the following, between 50% and 80% of patients will test positive for anti-PLA2R antibody with any of the available tests.12,13,20-22 This variability in sensitivity has more to do with the biology of the disease and perhaps ethnicity (eg, Japanese patients with primary MN have a lower rate of anti-PLA2R positivity23) rather than characteristics of the assays used.

The original discovery of PLA2R and early clinical studies relied on Western blotting, which is both sensitive and very specific for the detection of anti-PLA2R when recombinant human PLA2R is used as the antigen. However, the technique is costly, labor intensive, and impractical for routine clinical use. In 2014, the US Food and Drug Administration approved the first commercially available tests for anti-PLA2R, an indirect IF assay (IIFA) and an enzyme-linked immunosorbent assay (ELISA), 2 tests that had first become available in Europe and were widely used in the workup of patients with nephrotic syndrome.23 Although the IIFA is relatively high throughput, anti-PLA2R titers are semiquantitative and observer dependent, and reactivity with other baseline cell antigens may occasionally predispose to equivocal results. It is generally used as an initial screening assay, much like antineutrophil cytoplasmic antibody assays, before proceeding to the high-throughput and more quantitative and specific ELISA. As illustrated in Fig 2, compared with the Western blot assay for anti-PLA2R, the commercial IIFA and ELISA tests are highly specific for primary MN versus secondary MN and other forms of glomerular disease, although the ELISA is somewhat less sensitive using the recommended cutoff for positivity. These results are similar to those reported by other investigators with respect to these commercial assays13,24 and an independent ELISA25 and luminex assay.26 However, we should point out that occasional cases of MN with a positive test result for anti-PLA2R have been described in patients with cancer, lupus, hepatitis B virus infection, and other inflammatory and autoimmune diseases.27-30 Whether these are real secondary cases of MN or the chance association of PLA2R-associated primary MN in patients with other common diseases must await the test of time. A notable exception is a study from Shanghai that found a high proportion of patients with MN with hepatitis B surface antigen who were also positive for anti-PLA2R and exhibited colocalization of the viral antigen and PLA2R in glomerular immune deposits.31 We await confirmation of these findings with interest.

Perhaps most important is the fact that seropositivity for anti-PLA2R has not been found in any proteinuric kidney diseases other than MN.11,27,29,32 In other words, any patient with nephrotic syndrome who tests positive for anti-PLA2R is almost certain to have MN. This is important in patients for whom kidney biopsy poses a high risk, such as those needing anticoagulation for thromboembolic disease and patients with a single kidney.

**Box 1. Membranous Nephropathy**

- A leading cause of nephrotic syndrome in adults
- Antibody-mediated podocytopathy
- Primary MN (majority)
  - Organ-specific autoimmune disease
    - Variable course: remission, persistent nephrotic syndrome, ESRD
  - PLA2R-associated ~80%
  - THSD7A-associated ~5%-10% (possibly population-dependent)
  - Recurrence posttransplantation
- Secondary: lupus, infection with hepatitis B virus or other agents, drugs, cancer
- Alloimmune: neonatal MN (anti-NEP), de novo post-kidney and stem cell transplantation MN

Abbreviations: ESRD, end-stage renal disease; MN, membranous nephropathy; NEP, neutrophil endopeptidase; PLA2R, phospholipase A2 receptor 1; THSD7A, thrombospondin type 1 domain-containing 7A.
Immunostaining for PLA2R on Kidney Biopsy: Another Sensitive and Specific Test for Primary MN

PLA2R is expressed on the cell body of human podocytes and their foot processes. When anti-PLA2R antibodies bind, the immune complexes are thought to aggregate and then be shed into the subepithelial space between the podocyte and glomerular basement membrane. Detection by immunostaining of PLA2R in subepithelial deposits in kidney tissue is a very sensitive and specific technique to diagnose PLA2R-associated MN and correlates well with serologic tests. However, the absence of circulating anti-PLA2R antibodies in serum of patients with biopsy-proven MN does not rule out the diagnosis of PLA2R-associated MN. As we discuss later, some patients may have positive PLA2R immunostaining of the subepithelial immune deposits on kidney biopsy, supporting the diagnosis of PLA2R-associated MN despite the absence of circulating anti-PLA2R antibodies. Interestingly, a minority of patients who are seropositive for anti-PLA2R antibodies exhibit no staining for PLA2R within the immune deposits of their corresponding biopsy specimens. This may represent masking by autoantibodies of epitopes recognized by the commercial antibody used for IF staining, but has not yet been fully explored.

The absence of PLA2R deposits in kidney tissues from most patients with secondary MN makes this test very specific for primary MN. However, a few patients with secondary MN diagnosed on the basis of concurrent lupus, cancer, sarcoidosis, or viral hepatitis have been reported to test positive for serum anti-PLA2R antibodies or have positive immunostaining test results for PLA2R on kidney biopsy. Interestingly, in almost all these patients, the deposited antibodies are predominantly IgG4, a feature classically associated with primary MN. Although more studies are needed to explain this phenomenon, we favor the probability that such patients have primary PLA2R-associated MN concomitant with, rather than secondary to, sarcoidosis, cancer, or hepatitis. However, we recognize the possibility that the associated conditions may represent a disease-precipitating “second hit” in a patient genetically and immunologically predisposed to develop MN (discussed next).

Clinical Use of Anti-PLA2R Seropositivity and Glomerular Immunostaining for PLA2R

To better understand the utility of anti-PLA2R antibody for the diagnosis and follow up of PLA2R-associated MN, it is helpful to consider the lag between antibody deposition, seropositivity, and clinical activity as measured by proteinuria. Early in the course of the disease, when anti-PLA2R antibodies are first produced, podocyte injury and proteinuria are induced when the antibodies bind to the antigen on podocytes and immune deposits containing both PLA2R and anti-PLA2R antibodies are formed. At this time, circulating anti-PLA2R antibodies might not be detectable using standard assays despite their presence in glomerular deposits because the kidney acts as a “sink” absorbing all detectable circulating anti-PLA2R antibodies. In such cases, PLA2R will be detectable in immune deposits by IF staining, thus providing evidence that the MN is PLA2R-associated. With ongoing immunologic activity and disease progression, the renal tissue becomes saturated with anti-PLA2R antibodies, seropositivity develops, and the available tests become valuable tools for the diagnosis and monitoring of disease activity. As patients enter an immunologic remission, anti-PLA2R disappears from the circulation but proteinuria may remain unresolved. If a kidney biopsy were to be performed at this stage, it is very likely that staining for PLA2R in immune deposits would still be present. These relationships are illustrated in Fig 3.
Given the association of MN with cancer, it is general practice to screen patients with MN for the presence of solid tumors. Although observations from prospectively followed up patient cohorts are lacking, current evidence suggests that most patients with cancer-associated MN do not have tissue or serologic evidence of PLA2R-associated MN, and the biopsy features are more consistent with secondary rather than primary MN. Conversely, when patients with PLA2R-associated MN develop cancer, it tends to occur months to years after the onset of MN, suggesting that it is unrelated. This means that a patient with PLA2R-associated MN need not undergo an extensive workup for malignancy beyond routine age-appropriate health maintenance tests, whereas PLA2R-negative cases require closer scrutiny.

**Correlation of Anti-PLA2R Antibodies With Clinical Activity and Prognostic Value of Titers**

Anti-PLA2R antibodies have emerged as an excellent biomarker of disease activity in primary MN. At presentation, 70% to 80% of patients with primary MN will test positive for serum anti-PLA2R antibodies. Several studies have shown a temporal relationship between the presence and levels of anti-PLA2R antibodies and the disease activity. Usually the spontaneous or treatment-induced decline or disappearance of circulating anti-PLA2R antibodies (so-called immunologic remission) precedes a corresponding clinical remission by a period of several months. Therefore, monitoring anti-PLA2R antibody levels in patients with PLA2R-associated primary MN might help anticipate a spontaneous remission and avoid immunosuppression if the levels are declining or avoid unnecessarily prolonged treatment in those with residual proteinuria in whom the circulating antibodies have disappeared. Although formal prospective studies are needed to determine whether there is value in monitoring anti-PLA2R antibody levels in patients in remission, existing retrospective studies on stored samples showed that clinical relapse is usually associated with the reappearance of anti-PLA2R antibodies.

Antibody titers may also be informative. In a study involving 82 patients with PLA2R-associated MN (as determined by ELISA and IIFA) reported by Hofstra et al, the antibody titer correlated well with baseline proteinuria, and spontaneous remission occurred most often in those with the lowest anti-PLA2R IgG4 titers. A recent prospective study from Hoxha et al showed a correlation between baseline anti-PLA2R antibody levels and disease activity as measured by proteinuria. Rate of remission and time to achieve clinical remission strongly correlated with baseline anti-PLA2R antibody levels, whereas a decrease in anti-PLA2R antibody levels was associated with improvement in proteinuria. Likewise, among 81 patients with PLA2R-associated MN studied by Ruggenenti et al, lower anti-PLA2R antibody titer at baseline and complete antibody depletion 6 months after induction treatment with rituximab strongly predicted remission. A 2009 study had reported that reduction of anti-PLA2R antibody titer precedes the decline in proteinuria by several months. In the Ruggenenti et al cohort, total reduction of anti-PLA2R levels was noted in all 25 patients who had a complete remission, and of those cases, 18 remained in clinical and serologic remission. However, the reappearance of circulating anti-PLA2R antibodies preceded disease relapse.

Anti-PLA2R antibody levels at the end of a therapeutic intervention may also predict the long-term clinical outcome. In a study by Bech et al, almost 60% of patients who had undetectable anti-PLA2R antibodies at the end of therapy remained in clinical remission, whereas all patients who had detectable anti-PLA2R antibody after therapy experienced clinical relapse. A potential refinement in testing for anti-PLA2R antibody was recently reported by Seitz-Polski et al, who examined the reactivity of MN patient sera with PLA2R from different species by ELISA and found that rabbit PLA2R was as effective as human PLA2R in detecting anti-PLA2R antibody in patients with active disease. However, reactivity with mouse PLA2R was better at identifying patients at greater risk for progression.

Whereas a low or decreasing anti-PLA2R antibody titer correlates with remission and a favorable prognosis, the prognostic significance of antibody titer at the time of diagnosis prior to treatment is less clear. High titers at the time of diagnosis are more likely to be associated with or the development of nephrotic syndrome rather than asymptomatic proteinuria. However, it remains uncertain whether they forecast a poor outcome. In a retrospective ELISA study of stored sera, prevalent patients with the highest titers at the time of diagnosis were most likely to have active disease and were at greater risk for experiencing declines in kidney function during follow-up. However, a prospective Korean study found that high levels of anti-PLA2R antibodies, as measured by Western blotting at the time of kidney biopsy, did not predict the probability of progressive kidney failure. The different conclusions of these 2 studies may have to do with lead-time bias in the former and/or the different assay methods. A prospective study of 118 patients with primary MN assessed the risk for kidney function decline (conservatively defined as increase in serum creatinine level by ≥25%, to a level ≥ 1.3 mg/dL) in...
terms of anti-PLA2R antibody titer measured within 6 months of kidney biopsy and prior to any immunosuppressive therapy. Multivariate analysis showed that high anti-PLA2R levels independently predicted loss of kidney function. Future prospective analyses should determine whether time-averaged autoantibody levels or the trajectory of these levels would be better indicators of risk than absolute titer at baseline.

In summary, measurement of anti-PLA2R antibody supports the diagnosis of primary MN, predicts who might have spontaneous remission, helps monitor the disease activity and response to therapy, identifies those at risk for progression, and, importantly, might help clinicians decide when to minimize or stop treatment.

Genetics of Primary MN

Although MN is not a typical Mendelian hereditary disease, it, like other systemic and organ-specific autoimmune diseases, has long been known to be associated with certain class II major histocompatibility (HLA class II antigen) immune response genes. In addition, soon after our report on PLA2R as the target antigen, studies of Asian patients with primary MN showed strong associations with certain coding variants in PLA2R1 that might have explained conformational changes in PLA2R and susceptibility to MN were it not for the fact that these variants are common in the general population (Fig 4). Likewise, results of a genome-wide association study in Europeans showed remarkably strong associations with HLA-DQA1 and a single-nucleotide polymorphism (SNP) in a noncoding portion of PLA2R1, but to date, no unique coding variants have been found in PLA2R1 that explain the association despite sequencing of the exons and splice sites and comparing results to the National Center for Biotechnology Information’s short genetic variations database (dbSNP) and the 1000 Genomes Project database. Although the HLA-DQA1 and PLA2R1 risk alleles were reported to be strongly associated with anti-PLA2R antibody seropositivity and glomerular PLA2R immunostaining in individuals of Chinese or European ancestry, the SNPs were the same common variants previously identified in earlier reports. Additional studies have suggested that the genetic influence of the HLA class II antigen and PLA2R1 variants might manifest in the severity of disease rather than in its initiation. Alternatively, we have proposed that the genetic susceptibility to primary MN may depend not on the presence of unique rare SNPs, but instead on the concurrence of common genetic variants in PLA2R1 and the predisposition to autoimmunity conferred by HLA-DQA1 in concert with an external trigger.

Defining the PLA2R Epitope(s)

When we first identified PLA2R as a major target antigen in primary MN and found that all reactive antisera identified the antigen only under nonreducing conditions, we reasoned that there might be a single conformation-dependent epitope. This seemed to fit with the observation that other members of the mannose receptor family are known to exist in either extended or bent configurations. The implications of this were potentially exciting. If there is a single epitope, one could envisage making small peptides containing the epitope to immunoabsorb the offending antibodies or serve as decoy antigens in vivo that block the antibodies from binding PLA2R, or even to restore self-tolerance by oral or nasal immunization. Evidence
that there is a universal epitope in the amino-terminal region was documented by 2 groups of investigators. Fresquet et al identified a 31-amino acid sequence in the ricin B (cysteine-rich) domain that blocked most of the anti-PLA2R antibody reactivity in patient sera, whereas Kao et al found that MN patient sera specifically recognized a protein complex consisting of the cysteine-rich fibronectin-like type II and first C-type lectin-like domain of PLA2R (Fig 4). Unfortunately, although all patients have reactivity to the epitope contained within the cysteine-rich domain, epitope spreading to other parts of the molecule will have occurred by the time patients present with clinical symptoms. Thus, the hope of a magic bullet to block reactivity or restore tolerance in MN has receded for the present, but defining the spread of epitopes may provide information on disease severity and prognosis.

**Predictive Value of Anti-PLA2R for Recurrence of MN After Kidney Transplantation**

Primary MN may recur after kidney transplantation. The incidence of recurrence ranges from 10% to 45%, reflecting differences between centers that perform biopsies and those that only perform biopsies for clinical indication. The presence of circulating anti-PLA2R antibodies at the time of kidney transplantation is associated with high risk for disease recurrence in the kidney transplant. Testing for anti-PLA2R antibodies at the time of transplantation might provide valuable information regarding the risk for primary MN recurrence in the kidney transplant. The first case report, published in 2010, demonstrated that the presence of anti-PLA2R antibodies in a patient at the time of kidney transplantation was associated with recurrence of primary MN. Treatment with rituximab resulted in clinical improvement, with a progressive decline in both proteinuria and anti-PLA2R antibody levels. This case report also highlighted the timeline of immunologic remission, which usually precedes clinical remission by a few months. Kattah et al reported that the presence of circulating anti-PLA2R antibodies at the time of kidney transplantation has an 83% positive predictive value for recurrent MN as assessed by protocol biopsy. Worsening clinical course and increasing proteinuria were seen in patients with persistent or reappearing anti-PLA2R antibodies after kidney transplantation, whereas little or no proteinuria was noted in patients with biopsy-proven recurrent MN, in whom the anti-PLA2R antibodies disappeared with standard transplant immunosuppression. Similar findings were recently reported in another cohort of patients with primary MN in which the presence of anti-PLA2R antibodies at the time of kidney transplantation had a 91% positive predictive value of disease recurrence. However, the probability that anti-PLA2R antibody seropositivity at the time of transplantation will lead to clinically significant recurrent MN in the transplant is likely influenced not only by the presence of the autoantibodies, but also by their titer. Donor and recipient relatedness, class II major histocompatibility complex interactions, and the potency of transplant immunosuppression are also likely to be influential.

Although the probability of histologic recurrence is high in patients with high anti-PLA2R antibody titers at the time of transplantation, some patients may experience recurrence despite a negative pretransplantation test result for anti-PLA2R antibodies. Some of these individuals become seropositive after transplantation, perhaps due to the awakening of memory cells; recurrence in other cases could be due to primary MN from causes unrelated to PLA2R, including anti-THSD7A antibodies. At present, it is difficult to assign a negative predictive value to a negative pretransplantation test result for anti-PLA2R antibodies, and the negative predictive value of 42% reported by Kattah et al may underestimate the value of a negative test result. This is because it has been difficult to ascertain how many patients who tested negative at the time of transplantation had PLA2R-associated MN. Such information is likely to become available as more patients with MN are tested for anti-PLA2R antibodies before they develop ESRD. Thus, testing for anti-PLA2R antibodies prior to transplantation in patients with MN has merit in that a positive test result heightens surveillance for recurrent disease but is not in itself a contraindication to transplantation. Conversely, a negative test result does not ensure that the disease will not recur.

**Role of Anti-PLA2R Antibodies in Distinguishing Recurrent From De Novo MN**

Testing for anti-PLA2R antibodies is also useful for distinguishing recurrent primary MN from de novo MN after kidney transplantation. De novo development of MN after kidney transplantation in patients who did not have MN as a cause of ESRD occurs occasionally and may be associated with evidence of antibody-mediated rejection and circulating donor-specific antibodies. Whereas IgG4 is usually the dominant or codominant IgG subclass deposited in recurrent MN, the IgG1 subclass predominates in de novo MN. Assays for circulating anti-PLA2R antibodies or staining for PLA2R on kidney biopsy specimens almost always gives negative results in patients with de novo MN. These findings suggest different pathogenic processes between recurrent primary MN and de novo MN after kidney transplantation. De novo MN is most likely the result of
Phospholipase A2 receptor 1; THSD7A, thrombospondin type 1 domain-containing 7A.

Future Directions

The discovery of autoantibodies to PLA2R and more recently to THSD7A has added a new dimension to the monitoring and treatment of MN because it has opened a window onto the immunologic course of disease (Box 2). We anticipate that future research will investigate whether a high positive predictive value of anti-PLA2R seropositivity will obviate the need for kidney biopsy in such patients, assist in the selection of appropriate immunologically active patients for therapeutic research studies, and ultimately help tailor the type and duration of therapy on an individualized basis. Understanding the repertoire of epitopes targeted in an individual may help predict disease severity and may someday lead to the development of small inhibitory peptides or even to tolerogens. Although patients with primary MN for which no association with PLA2R or THSD7A has been detected appear to behave similarly to their counterparts in terms of baseline characteristics, prognosis, and response to treatment, we anticipate that future research will identify the responsible antigen-autoantibody pairs in these individuals as well.

Acknowledgements

Support: This work was supported by research grants R01 DK097053 (to Dr. Beck), R01 DK090029 (to Dr. Salant), and NRSA T32 DK 007053 from the National Institutes of Health/ National Institute of Diabetes and Digestive and Kidney Diseases.

Financial Disclosure: Drs. Beck and Salant are coinventors on a patent entitled “Diagnostics for Membranous Nephropathy.” Dr. Salant has received grant support from Alexion, Pfizer for studies of experimental nephritis and has served as a consultant for Chugai, Actelion, and Astellas. Dr. Francis declares that he has no relevant financial interests.

References

Membranous Nephropathy


